Overview Dividends

(TWST) Twist Bioscience - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US90184D1000

Synthetic DNA, Gene Fragments, Oligo Pools, NGS Tools, Antibody Libraries

TWST EPS (Earnings per Share)

EPS Growth (3Y CAGR): 26.77%
EPS Trend (3Y Correlation): 60.6%

TWST Revenue

Revenue Growth (3Y CAGR): 20.66%
Revenue Trend (3Y Correlation): 99.1%

Risk via 10d forecast
Volatility	75.2%
Value at Risk 5%th	115%
Relative Tail Risk	-6.66%

Reward TTM
Sharpe Ratio	-0.42
Alpha	-62.37

Character TTM
Hurst Exponent	0.412
Beta	1.801
Beta Downside	1.335

Drawdowns 3y
Max DD	62.82%
Mean DD	28.56%
Median DD	27.72%

Description: TWST Twist Bioscience November 12, 2025

Twist Bioscience Corp. (NASDAQ:TWST) manufactures synthetic DNA-based products, supplying gene fragments, oligo pools, and custom immunoglobulin G proteins for applications ranging from therapeutics and diagnostics to data storage and agricultural biotech. Its portfolio also includes next-generation sequencing (NGS) kits, methylation detection assays, and a suite of synthetic viral controls (e.g., SARS-CoV-2, monkeypox) that support assay development and research panels for respiratory pathogens.

Key recent metrics: FY 2023 revenue reached approximately $1.0 billion, up ~35 % YoY, driven by strong demand for high-throughput DNA synthesis in CRISPR-based drug discovery and expanding NGS diagnostic markets. The global synthetic DNA market is projected to grow at a CAGR of 15 % through 2030, with biotech R&D spend and the rise of DNA-based data storage acting as primary tailwinds. Twist’s strategic alliance with bitBiome enhances its capability to deliver large-scale, high-accuracy DNA libraries for antibody engineering, a segment that has seen a 20 % increase in funding across the pharma sector in the past year.

For a deeper, data-driven assessment of Twist’s valuation and competitive positioning, you may find ValueRay’s analytical toolkit worth exploring.

TWST Stock Overview

Market Cap in USD	1,869m
Sub-Industry	Biotechnology
IPO / Inception	2018-10-31
Return 12m vs S&P 500	-43.9%
Analyst Rating	4.17 of 5

TWST Dividends

Currently no dividends paid

TWST Growth Ratios

CAGR 3y	2.72%
CAGR/Max DD Calmar Ratio	0.04
CAGR/Mean DD Pain Ratio	0.10
Current Volume	5759.2k
Average Volume	1422k

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (-85.2m TTM) > 0 and > 6% of Revenue (6% = 21.7m TTM)

FCFTA -0.11 (>2.0%) and ΔFCFTA 1.07pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 69.76% (prev 97.58%; Δ -27.83pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.08 (>3.0%) and CFO -51.1m > Net Income -85.2m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.90 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (61.2m) change vs 12m ago 5.19% (target <= -2.0% for YES)

Gross Margin 49.24% (prev 40.53%; Δ 8.72pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 56.53% (prev 46.26%; Δ 10.27pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -560.5 (EBITDA TTM -123.5m / Interest Expense TTM 243.0k) >= 6 (WARN >= 3)

Altman Z'' -13.61

(A) 0.39 = (Total Current Assets 339.8m - Total Current Liabilities 87.1m) / Total Assets 643.6m

(B) -2.01 = Retained Earnings (Balance) -1.29b / Total Assets 643.6m

warn (B) unusual magnitude: -2.01 — check mapping/units

(D) -7.82 = Book Value of Equity -1.29b / Total Liabilities 165.4m

Total Rating: -13.61 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 38.08

1. Piotroski 2.50pt = -2.50

2. FCF Yield -4.05% = -2.03

3. FCF Margin -18.97% = -7.11

4. Debt/Equity 0.16 = 2.49

5. Debt/Ebitda 1.00 = 1.77

6. ROIC - WACC (= -41.38)% = -12.50

7. RoE -18.45% = -2.50

8. Rev. Trend 99.09% = 7.43

9. EPS Trend 60.61% = 3.03

What is the price of TWST shares?

As of November 17, 2025, the stock is trading at USD 26.87 with a total of 5,759,225 shares traded.
Over the past week, the price has changed by -13.21%, over one month by -12.62%, over three months by -4.10% and over the past year by -35.14%.

Is Twist Bioscience a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Twist Bioscience (NASDAQ:TWST) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 38.08 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TWST is around 21.69 USD . This means that TWST is currently overvalued and has a potential downside of -19.28%.

Is TWST a buy, sell or hold?

Twist Bioscience has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy TWST.

Strong Buy: 6
Buy: 3
Hold: 2
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the TWST price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	39.6	47.5%
Analysts Target Price	39.6	47.5%
ValueRay Target Price	25	-7%

TWST Fundamental Data Overview November 11, 2025

Market Cap USD = 1.87b (1.87b USD * 1.0 USD.USD)
P/S = 5.1585
P/B = 3.9054
Beta = 2.244
Revenue TTM = 362.3m USD
EBIT TTM = -136.2m USD
EBITDA TTM = -123.5m USD
Long Term Debt = 65.1m USD (from longTermDebtTotal, two quarters ago)
Short Term Debt = 15.5m USD (from shortTermDebt, last quarter)
Debt = 78.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -123.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.70b USD (1.87b + Debt 78.2m - CCE 250.8m)
Interest Coverage Ratio = -560.5 (Ebit TTM -136.2m / Interest Expense TTM 243.0k)
FCF Yield = -4.05% (FCF TTM -68.7m / Enterprise Value 1.70b)
FCF Margin = -18.97% (FCF TTM -68.7m / Revenue TTM 362.3m)
Net Margin = -23.51% (Net Income TTM -85.2m / Revenue TTM 362.3m)
Gross Margin = 49.24% ((Revenue TTM 362.3m - Cost of Revenue TTM 183.9m) / Revenue TTM)
Gross Margin QoQ = 53.40% (prev 49.60%)
Tobins Q-Ratio = 2.64 (Enterprise Value 1.70b / Total Assets 643.6m)
Interest Expense / Debt = 0.24% (Interest Expense 190.0k / Debt 78.2m)
Taxrate = 0.93% (191.0k / 20.6m)
NOPAT = -134.9m (EBIT -136.2m * (1 - 0.93%)) [loss with tax shield]
Current Ratio = 3.90 (Total Current Assets 339.8m / Total Current Liabilities 87.1m)
Debt / Equity = 0.16 (Debt 78.2m / totalStockholderEquity, last quarter 478.2m)
Debt / EBITDA = 1.00 (negative EBITDA) (Net Debt -123.2m / EBITDA -123.5m)
Debt / FCF = 1.79 (negative FCF - burning cash) (Net Debt -123.2m / FCF TTM -68.7m)
Total Stockholder Equity = 461.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.24% (Net Income -85.2m / Total Assets 643.6m)
RoE = -18.45% (Net Income TTM -85.2m / Total Stockholder Equity 461.7m)
RoCE = -25.85% (EBIT -136.2m / Capital Employed (Equity 461.7m + L.T.Debt 65.1m))
RoIC = -29.22% (negative operating profit) (NOPAT -134.9m / Invested Capital 461.7m)
WACC = 12.15% (E(1.87b)/V(1.95b) * Re(12.65%) + D(78.2m)/V(1.95b) * Rd(0.24%) * (1-Tc(0.01)))
Discount Rate = 12.65% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.14%
Fair Price DCF = unknown (Cash Flow -68.7m)
EPS Correlation: 60.61 | EPS CAGR: 26.77% | SUE: 1.81 | # QB: 1
Revenue Correlation: 99.09 | Revenue CAGR: 20.66% | SUE: 0.31 | # QB: 0

Additional Sources for TWST Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle